A 130-year-old justice declines to retire, and the succession line stalls

Who ages first? Ask that at the gate of the Meridian Longevity Institute's Earthside clinic, where a hundred-odd young people have folded themselves onto the rectenna-field grass for a ninth straight day, and you won't wait long for an answer. They call it a succession sit-in. The name is the argument.

Justice Aurelio Vance, age 130, announced this week that he will serve a third term on the Charter Court. This is the body that rules on whether a charter may bind its grandchildren, whether a treaty power may throttle a settlement's energy share, and, one might think, whether a public post may be held without end. Justice Vance sees no contradiction. "The Court is not a queue," he said in a statement read by a clerk. "It is a trust. I have not been discharged of it."

The succession line beneath him has now stalled for a third consecutive term. Two nominees who might have taken the seat have themselves grown old waiting. That used to be a joke. Aging, for those without access, is still fate. For those with it, it's a schedule they set for themselves.

So put the two facts side by side, because the Institute would rather you didn't. The coastal cohort waitlist holds just over forty thousand names and moved 1.9 percent last quarter — a glacier's pace, in an age that stopped the glaciers. Justice Vance, whose ninth decade the therapies have already carried past its natural close, renewed both his treatment and his tenure in the same season a nurse on that list watched it not move an inch.

The sit-in's organizers know these numbers cold. "We were told the incumbents would step aside when the time came," said Ilse Marnat, 34, who has camped at the clinic gate since the first night. "The therapies moved the time. Nobody moved the incumbents." She had three questions for anyone who'd listen. Who decided a justice's third term outranks our first careers? Who audits that decision? And who benefits while the answer stays filed under 'clinical prioritization'?

The Institute's ethics board offers what it calls a remedy. Its 'renewal value' proposal, floated earlier this year, would advance an applicant on the waitlist in exchange for a vacated post — treatment for a chair, years for a seat. Bioethicists on the board call it dignified turnover. Justice Vance, through his clerk, called it "a bribe wearing a lab coat." The sit-in itself is split. Some see a lever. Others see a market in resignation letters that only the powerful could ever afford to decline.

Here's what nobody disputes: who governs the list. Seven of the eleven triage board members have received tier-one therapy themselves. None has disclosed a place on any waitlist. I asked the board to name a single member who had ever waited. The reply came back in writing: the composition of the board is "not a matter of public prioritization."

Outside the clinic, the grass is worn to dirt where the young sit. Justice Vance is sworn to his third term at week's end.